Outlook Therapeutics® Streamlines Operations
13. Dezember 2024 16:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
04. Dezember 2024 08:05 ET
|
Outlook Therapeutics, Inc.
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of...
Outlook Therapeutics® Announces Executive Leadership Transition
03. Dezember 2024 16:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
27. November 2024 06:50 ET
|
Outlook Therapeutics, Inc.
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
06. November 2024 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
17. Oktober 2024 09:00 ET
|
Outlook Therapeutics, Inc.
Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the...
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
16. September 2024 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
13. September 2024 09:05 ET
|
Outlook Therapeutics, Inc.
Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory...
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
04. September 2024 08:35 ET
|
Outlook Therapeutics, Inc.
Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03. September 2024 08:45 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...